EO-1022 / Elevation Oncology - LARVOL DELTA

Preclinical discovery and characterization of EO-1022, a site-specific glycan-conjugated anti-HER3 vc-MMAE ADC for treating solid tumors (AACR 2025) - "EO-1022 is comprised of the highly selective and clinically validated HER3 antibody, seribantumab, that is site-specifically glycan-conjugated with a cleavable valine-citrulline linker and monomethyl auristatin E (MMAE) payload to give a drug-to-antibody ratio (DAR) of 4. EO-1022 was evaluated in vitro and in vivo, with patritumab deruxtecan (patri-DXd) as a comparator. EO-1022 demonstrated target-dependent in vitro cytotoxicity and in vivo anti-tumor activity in a HER3-expressing breast cancer CDX model. Additional results on the optimization and characterization of EO-1022 will be presented, including bystander effect assays and in vivo models of HER3-positive breast cancer and EGFR mutant NSCLC. Results from preclinical studies highlight the therapeutic potential of EO-1022 for patients living with HER3-expressing cancers."

Late-breaking abstract • Preclinical • Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025 (PRNewswire) - "Elevation Oncology scientists will present in vitro and in vivo data that show: EO-1022 is highly stable in human serum, with a homogenous DAR of 4 and minimal free payload compared to seribantumab-vcMMAE and patritumab-DXd, two benchmark HER3 ADCs, both of which use stochastic conjugation. These findings illustrate that a key feature of EO-1022 is minimal systemic exposure to free payload, potentially resulting in reduced payload-associated toxicity in patients and an improved safety profile; EO-1022 exhibits potent in vitro cytotoxicity that is dependent on HER3 expression levels; EO-1022 elicits anti-tumor activity in in vivo models of low, medium and high HER3 expression levels, including in a patient derived xenograft (PDX) model of low HER3-expressing EGFR-mutant lung cancer."

Preclinical • Lung Cancer • ERBB3

Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025 (PRNewswire) - "Elevation Oncology, Inc...announced that it will present preclinical data for its novel HER3 ADC, EO-1022, in a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, being held April 25-30 in Chicago, Illinois.... Elevation Oncology is developing EO-1022 for the treatment of solid tumors that express HER3, including breast cancer and non-small cell lung cancer, and expects to file an IND application in 2026."

IND • Preclinical • Breast Cancer • Non Small Cell Lung Cancer • Solid Tumor

Elevation Oncology…Advancing EO-1022, While Evaluating Strategic Options (PRNewswire) - "Elevation Oncology will continue to advance EO-1022, a HER3 ADC for the treatment of patients with HER3-expressing solid tumors....Plan to present preclinical data for EO-1022 at AACR Annual Meeting 2025 and to file an Investigational New Drug (IND) application in 2026."

IND • Preclinical • Solid Tumor

Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements (PRNewswire) - "Expected Upcoming Milestones:...EO-1022: (i) Present preclinical data for EO-1022 at AACR Annual Meeting in the second quarter of 2025; (ii) File an IND application for EO-1022 in 2026."

IND • Preclinical • Solid Tumor

Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors (PRNewswire) - "Elevation Oncology...announced the nomination of EO-1022 as its HER3 ADC development candidate. EO-1022 is currently progressing through preclinical development, and Elevation Oncology expects to file an investigational new drug (IND) application in 2026....EO-1022 is a differentiated ADC containing seribantumab, an anti-HER3 monoclonal antibody (mAb), and a monomethyl auristatin E (MMAE) payload, with site-specific conjugation to the glycan. EO-1022 is being developed for the treatment of patients living with solid tumors that express HER3....'We look forward to sharing preclinical data for EO-1022 in the first half of 2025, as we continue to advance this asset toward the clinic'."

IND • Pipeline update • Preclinical • Solid Tumor

Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements (PRNewswire) - "Elevation Oncology...announced financial results for the second quarter ended June 30, 2024, and highlighted recent business achievements...Nominate development candidate from HER3-ADC program in the second half of 2024...Research and development (R&D) expenses for the second quarter of 2024 were $6.6 million, compared to $6.0 million for the second quarter of 2023. The increase in R&D expenses in the second quarter of 2024 was primarily due to increased EO-3021 clinical trial expenses....Elevation Oncology will host a live conference call and webcast at 8:30 a.m. ET today to discuss the initial EO-3021 safety and efficacy data announced today."

Commercial • New molecule • P1 data • Esophageal Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024 (PRNewswire) - "Elevation Oncology...announced new preclinical data demonstrating proof-of-concept for its differentiated HER3-ADC program. The data will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024....In cytotoxicity assays, HER3-ADC1 displayed HER3-dependent cell killing and outperformed a benchmark HER3-ADC with a deruxtecan payload, which is currently in clinical development. In a patient derived xenograft (PDX) model of pancreatic cancer with high HER3 expression, HER3-ADC1 induced tumor regression, whereas an isotype-MMAE control and a benchmark HER3-ADC with a deruxtecan payload had only a modest effect."

Preclinical • Pancreatic Cancer

Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024 (PRNewswire) - "Elevation Oncology...announced that it will present preclinical proof-of-concept data for its differentiated HER3-targeting antibody-drug conjugate (ADC) program in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024....'We look forward to nominating a development candidate this year and to the advancement of our HER3-ADC program toward the clinic'..."

Pipeline update • Preclinical • Solid Tumor

Elevation Oncology Announces Program Updates and Upcoming 2024 Milestones (PRNewswire) - "Elevation Oncology plans to expand its clinical development program to evaluate EO-3021 in combination. The Company believes a combination approach has the potential to offer optimal outcomes to patients, particularly in the gastric cancer setting, and plans to explore combination strategies with both immunotherapy and targeted agents. Elevation Oncology expects to share details on its planned Phase 1 combination study in the first half of 2024...Elevation Oncology's second program is a differentiated HER3-targeting ADC....Elevation Oncology is currently evaluating its HER3-ADC program and plans to nominate a development candidate in 2024."

New molecule • New P1 trial • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor